Bionime Past Earnings Performance

Past criteria checks 0/6

Bionime's earnings have been declining at an average annual rate of -33.2%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been declining at an average rate of 1% per year.

Key information

-33.2%

Earnings growth rate

-34.0%

EPS growth rate

Medical Equipment Industry Growth11.5%
Revenue growth rate-1.0%
Return on equity-4.5%
Net Margin-4.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Jul 22
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

Jul 01
Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Apr 29
These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Mar 23
Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Mar 05
Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Feb 15
Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Feb 01
Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

How Has Bionime (TPE:4737) Allocated Its Capital?

Jan 19
How Has Bionime (TPE:4737) Allocated Its Capital?

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

Jan 06
A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Dec 22
A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Dec 09
Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Nov 24
Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Revenue & Expenses Breakdown

How Bionime makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TWSE:4737 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,921-83594342
30 Jun 241,858-40559303
31 Mar 241,8097507247
31 Dec 231,7566487242
30 Sep 231,86322538218
30 Jun 232,00243594211
31 Mar 232,15072649207
31 Dec 222,21191671202
30 Sep 222,09195588194
30 Jun 222,023115567189
31 Mar 221,86289525185
31 Dec 211,85087520188
30 Sep 211,879101546188
30 Jun 211,832111534209
31 Mar 211,77983532231
31 Dec 201,66962480248
30 Sep 201,91373531261
30 Jun 201,95138532266
31 Mar 202,16291558276
31 Dec 192,173106537255
30 Sep 192,043112468254
30 Jun 192,113132473233
31 Mar 191,986121452205
31 Dec 182,007128475201
30 Sep 181,962114475190
30 Jun 181,842135438171
31 Mar 181,821137396165
31 Dec 171,820150387160
30 Sep 171,771174369140
30 Jun 171,780181365146
31 Mar 171,791192378145
31 Dec 161,740179372140
30 Sep 161,654143375137
30 Jun 161,637119386133
31 Mar 161,57191389124
31 Dec 151,61099394118
30 Sep 151,634101386109
30 Jun 151,5918235397
31 Mar 151,5717235193
31 Dec 141,5255435392
30 Sep 141,44622335103
30 Jun 141,45943353106
31 Mar 141,53672376102

Quality Earnings: 4737 is currently unprofitable.

Growing Profit Margin: 4737 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4737 is unprofitable, and losses have increased over the past 5 years at a rate of 33.2% per year.

Accelerating Growth: Unable to compare 4737's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4737 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5%).


Return on Equity

High ROE: 4737 has a negative Return on Equity (-4.47%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 09:34
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bionime Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ryan LiuIBTS Investment Consulting Co., Ltd.
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Hsiu Chi LinMasterlink Securities Corp.